A. Tsuboya

Minimal contribution of the hepatic uptake transporter OATP1B1 to the inter-individual variability in SN-38 pharmacokinetics in cancer patients without severe renal failure

H. Kusuhara, T. Tsunoda, K. Fujita, 2021, Cancer Chemotherapy and Pharmacology.

Coadministration of cytotoxic chemotherapeutic agents with irinotecan is a risk factor for irinotecan-induced cholinergic syndrome in Japanese patients with cancer

Y. Sasaki, Ken-Ichi Fujita, D. Kamei, 2018, International Journal of Clinical Oncology.

Protocol of a randomised controlled trial on the efficacy of medication optimisation in elderly inpatients: medication optimisation protocol efficacy for geriatric inpatients (MPEG) trial

S. Albert, C. Okuse, Tsubasa Sakai, 2020, BMJ Open.

Study protocol for SPARED trial: randomised non-inferiority phase III trial comparing dexamethasone on day 1 with dexamethasone on days 1–4, combined with neurokinin-1 receptor antagonist, palonosetron and olanzapine (5 mg) in patients receiving cisplatin-based chemotherapy

H. Arioka, T. Miyaji, Takuhiro Yamaguchi, 2020, BMJ Open.

Placebo-Controlled, Double-Blinded Phase III Study Comparing Dexamethasone on Day 1 With Dexamethasone on Days 1 to 3 With Combined Neurokinin-1 Receptor Antagonist and Palonosetron in High-Emetogenic Chemotherapy.

T. Yamanaka, M. Ando, M. Fukuda, 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Placebo-controlled phase III study comparing dexamethasone on day 1 to on day 1-3 with NK1 receptor antagonist and palonosetoron in high emetogenic chemotherapy.

T. Yamanaka, M. Ando, M. Fukuda, 2016 .

LBA63 Placebo-controlled, double-blinded phase Ⅲ study comparing dexamethasone on day 1 with dexamethasone on days 1 to 4, with combined neurokinin-1 receptor antagonist, palonosetron, and olanzapine in patients receiving cisplatin-containing highly emetogenic chemotherapy: SPARED trial

H. Arioka, T. Miyaji, C. Katada, 2021, Annals of Oncology.

Dexamethasone-sparing on days 2-4 with combined palonosetron, neurokinin-1 receptor antagonist, and olanzapine in cisplatin: a randomized phase III trial (SPARED Trial).

T. Miyaji, C. Katada, Y. Ohno, 2023, British journal of cancer.